Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
    • Philanthropic Consulting
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More

BY Benzinga
— 8:33 AM ET 05/09/2022

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF NASDAQ:IBB, considered a proxy for the sector, shed close to 3 percent during the week.

Penny stock and digital therapeutics company Better Therapeutics, Inc. NASDAQ:BTTX more than doubled despite a lack of any meaningful catalysts. On the other hand, Connect Biopharma Holdings Limited NASDAQ:CNTB lost more than half its market value after its investigational asset that is being evaluated for ulcerative colitis flunked a mid-stage trial.

Earnings news flow also continued to move stocks in the space.

Here are the key catalysts for biotech stocks in the unfolding week:

Conferences

World Federation of Hemophilia, or WFH, 2022 World Congress: May 8-11, in Montreal, Canada, as well as virtually
BofA Securities 2022 Healthcare Conference: May 9-13, in Las Vegas, Nevada
Psych Symposium: May 11, in London, U.K.
American Thoracic Society, or ATS, 2022 International Conference: May 13-18, in San Francisco, California

FDA Meeting

Veru, Inc. NASDAQ:VERU has a pre-emergency use authorization meeting scheduled with the Food and Drug Administration on Tuesday for sabizabulin, its COVID-19 treatment.

Clinical Readouts/Presentations

Mereo BioPharma Group plc NASDAQ:MREO is scheduled to host a conference call Monday, at 10:30 a.m. ET, to review top-line clinical data from its Phase 2 Study of Alvelestat in Alpha-1 antitrypsin deficiency-associated emphysema.

BioMarin Pharmaceutical, Inc. NASDAQ:BMRN will present at the WFH Congress Phase 3 data for valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A.

Mind Medicine, Inc. NASDAQ:MNMD is due to present at the Psych Symposium, results from the Phase 2 investigator-initiated clinical trial of LSD in the treatment of anxiety disorders. The presentation is scheduled for Wednesday.

Related Link: Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates

Earnings

The earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule

Monday

FibroGen, Inc. NASDAQ:FGEN (after the close)
Heron Therapeutics, Inc. NASDAQ:HRTX (after the close)
Novavax, Inc. NASDAQ:NVAX (after the close)
ICU Medical, Inc. NASDAQ:ICUI (after the close)
Y-mAbs Therapeutics, Inc. NASDAQ:YMAB (after the close)

Tuesday

Bausch Health Companies Inc. NYSE:BHC (before the market open)
Haemonetics Corporation NYSE:HAE (before the market open)
Inovio Pharmaceuticals, Inc. NASDAQ:INO (after the close)
OraSure Technologies, Inc. NASDAQ:OSUR (after the close)

Wednesday

ADMA Biologics, Inc. NASDAQ:ADMA after the close)

Thursday

Altimmune, Inc. NASDAQ:ALT (before the market open)

Friday

PLx Pharma Inc. NASDAQ:PLXP (before the market open)

Related Link: Here's Why Moderna Shares Are Trading Higher After Q1 Earnings Today

IPOs

Seattle, Washington-based Intrinsic Medicine, Inc. NASDAQ:INRX has filed with the SEC regarding the initial public offering of 4.12 million shares of its common stock and warrants to purchase common stock. Selling shareholders will offer up to 13.62 million of the company's common stock.

Intrinsic Medicine is a preclinical-stage therapeutics company leveraging synthetic biology-manufactured human identical milk oligosaccharide molecules as new medicines to treat patients underserved by current treatment options. The company expects to price the common stock offering between $5 and $7. It has applied for listing its shares on the Nasdaq under the ticker symbol "INRX."

More FGEN News

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session
    Benzinga - 8:18 AM ET 05/09/2022
  • 20 Stocks Moving in Monday's Pre-Market Session
    Benzinga - 7:08 AM ET 05/09/2022
  • Earnings Scheduled For May 9, 2022
    Benzinga - 4:52 AM ET 05/09/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close